

Johnson & Johnson Innovative Medicine
Selected Novel Therapies - Recent Approvals/Potential Filings*
(2023-2030 Key Filings, As Outlined at 2023 Enterprise Business Review)

Selective Highlights as of July 17, 2024

Assets with \$5B+ PYS Potential

Oncology

CD20-based CAR-T
Lymphoma

TALVEY (talquetamab)
Relapsed Refractory Multiple myeloma

TARIS Platform
Bladder Cancer

RYBREVANT/ lazertinib
Non Small Cell Lung Cancer

Neuroscience

nipocalimab
Autoantibody Diseases

posdinemab
Alzheimer's Disease

Immunology

JNJ-2113 Targeted oral peptide
Autoimmune Diseases

Select Other Areas

Milvexian
Thrombosis

Assets with \$1 – 5B PYS Potential

Oncology

AKEEGA (niraparib/abiraterone)
 Metastatic castration-resistant prostate cancer (mCRPC)

JNJ-5322 (BCMA/GPRC5D/CD3)
Hematologic Malignancies

JNJ-8543 (CD79/CD20/CD3)
Hematologic Malignancies

JNJ-8343 KLK2 / CD3
Prostate Cancer

JNJ-6420 225Ac KLK2
Prostate Cancer

Menin-KMT2A inhibitor
Hematologic Malignancies

Neuroscience

JNJ-1887 sCD59
Geographic Atrophy

RPGR Gene Therapy
Retinitis Pigmentosa

seltorexant
Adjunctive treatment for major depressive disorder with insomnia symptoms

Aticaprant
Adjunctive treatment for major depressive disorder

Immunology

JNJ-1459
Psoriasis

JNJ-4804 Co-antibody Therapeutic
Inflammatory Bowel Disease

Select Other Areas

ExPEC
Multivalent Vaccine (9V)

Submitted in US or EU

Approved in US or EU

PYS refers to peak year non-risk adjusted operational sales, including partner sales. Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

Niraparib licensed from Tesaro; ExPEC investigational vaccine program developed and commercialized in partnership with Sanofi; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab); JNJ-1459 was developed through a collaboration with X-CHEM; Lazertinib licensed from Yuhuan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; JNJ-1887 acquired from Hemera Biosciences; Milvexian co-developed with Bristol Myers Squibb; (CAR) T-cell therapies [JNJ-90014496 and JNJ-90009530] AbelZeta collaboration and license agreement; JNJ-2113 licensed from and co-developing with Protagonist Therapeutics, Inc.;